Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:DRUG NASDAQ:ESPR NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$24.65+2.4%$22.78$2.15▼$28.44$791.75M1.62268,920 shs34,396 shsDRUGBright Minds Biosciences$88.48-0.4%$80.53$23.17▼$123.75$860.86M-5.35171,611 shs26,889 shsESPREsperion Therapeutics$3.15+0.2%$2.53$0.69▼$4.18$809.54M0.918.57 million shs2.29 million shsRNACCartesian Therapeutics$8.53+4.5%$6.91$5.60▼$15.57$250.63M0.58180,471 shs32,224 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience-2.29%-7.19%+12.62%+55.57%+1,002.03%DRUGBright Minds Biosciences-0.09%+0.99%+15.55%+16.91%+193.04%ESPREsperion Therapeutics-0.32%+57.00%+35.93%-7.65%+260.92%RNACCartesian Therapeutics-2.16%+31.19%+29.94%+25.73%-19.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$24.65+2.4%$22.78$2.15▼$28.44$791.75M1.62268,920 shs34,396 shsDRUGBright Minds Biosciences$88.48-0.4%$80.53$23.17▼$123.75$860.86M-5.35171,611 shs26,889 shsESPREsperion Therapeutics$3.15+0.2%$2.53$0.69▼$4.18$809.54M0.918.57 million shs2.29 million shsRNACCartesian Therapeutics$8.53+4.5%$6.91$5.60▼$15.57$250.63M0.58180,471 shs32,224 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience-2.29%-7.19%+12.62%+55.57%+1,002.03%DRUGBright Minds Biosciences-0.09%+0.99%+15.55%+16.91%+193.04%ESPREsperion Therapeutics-0.32%+57.00%+35.93%-7.65%+260.92%RNACCartesian Therapeutics-2.16%+31.19%+29.94%+25.73%-19.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.67Moderate Buy$35.1342.47% UpsideDRUGBright Minds Biosciences 2.86Moderate Buy$128.6045.35% UpsideESPREsperion Therapeutics 2.00Hold$5.5476.15% UpsideRNACCartesian Therapeutics 2.67Moderate Buy$34.00298.59% UpsideCurrent Analyst Ratings BreakdownLatest RNAC, DRUG, ANRO, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ANROAlto Neuroscience Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.005/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026ANROAlto Neuroscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.165/1/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.004/22/2026ANROAlto Neuroscience Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/21/2026ESPREsperion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$4.87 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/AESPREsperion Therapeutics$403.14M2.01N/AN/A($1.26) per share-2.50RNACCartesian Therapeutics$1.78M141.20N/AN/A($5.04) per share-1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$63.24M-$2.18N/AN/AN/AN/A-47.64%-37.83%5/13/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$1.93N/AN/AN/AN/A-28.62%-28.08%5/15/2026 (Estimated)ESPREsperion Therapeutics-$22.68M-$0.17N/A14.302.56-3.66%N/A-3.93%N/ARNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%N/ALatest RNAC, DRUG, ANRO, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026DRUGBright Minds Biosciences-$0.9240N/AN/AN/AN/AN/A5/13/2026Q1 2026ANROAlto Neuroscience-$0.56N/AN/AN/AN/AN/A4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million3/16/2026Q4 2025ANROAlto Neuroscience-$0.56-$0.45+$0.11-$0.45N/AN/A3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 million3/9/2026Q4 2025RNACCartesian Therapeutics-$0.82-$1.38-$0.56-$3.57$0.10 million$0.95 million2/12/2026Q1 2026DRUGBright Minds Biosciences-$0.98-$0.70+$0.28-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1215.6915.69DRUGBright Minds BiosciencesN/A57.3857.38ESPREsperion TherapeuticsN/A1.541.19RNACCartesian TherapeuticsN/A7.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/ADRUGBright Minds Biosciences40.52%ESPREsperion Therapeutics47.39%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.25%DRUGBright Minds Biosciences42.66%ESPREsperion Therapeutics1.70%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A31.95 million28.35 millionN/ADRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableESPREsperion Therapeutics200257.41 million253.03 millionOptionableRNACCartesian Therapeutics6429.38 million11.67 millionOptionableRNAC, DRUG, ANRO, and ESPR HeadlinesRecent News About These CompaniesPrivium Fund Management B.V. Invests $1.24 Million in Cartesian Therapeutics, Inc. $RNACMay 6 at 6:47 AM | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 4, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cartesian Therapeutics (RNAC) and Humana (HUM)May 2, 2026 | theglobeandmail.comWedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)May 1, 2026 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings ResultsApril 30, 2026 | marketbeat.comCartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesApril 30, 2026 | zacks.comCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comCartesian Therapeutics (RNAC) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 21, 2026 | marketbeat.comCartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?April 20, 2026 | zacks.comCartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% Higher - Time to Buy?April 18, 2026 | marketbeat.comCartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 14, 2026 | seekingalpha.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2026 | globenewswire.comCartesian Therapeutics (NASDAQ:RNAC) Stock, Short Interest ReportMarch 10, 2026 | benzinga.comCantor Fitzgerald upgrades Cartesian Therapeutics (RNAC)March 10, 2026 | msn.comCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 9, 2026 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 8.15%February 18, 2026 | aaii.comACartesian Therapeutics Announces New Employment Inducement GrantsFebruary 3, 2026 | globenewswire.comCartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?January 14, 2026 | zacks.comCartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile DermatomyositisJanuary 9, 2026 | quiverquant.comQCartesian Therapeutics (NASDAQ:RNAC) CFO Blaine Davis Sells 10,591 SharesJanuary 9, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTariffs Rose: 1 Steelmaker Thrived, 1 Still StrugglesBy Chris Markoch | April 23, 20263 Ways to Invest in the Growing GLP-1 Weight Loss MarketBy Nathan Reiff | April 17, 2026Why Simply Good Foods Stock Just Had Its Worst Day in YearsBy Chris Markoch | April 10, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentBy Nathan Reiff | May 1, 2026RNAC, DRUG, ANRO, and ESPR Company DescriptionsAlto Neuroscience NYSE:ANRO$24.65 +0.58 (+2.43%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Bright Minds Biosciences NASDAQ:DRUG$88.48 -0.35 (-0.39%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Esperion Therapeutics NASDAQ:ESPR$3.14 +0.01 (+0.16%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Cartesian Therapeutics NASDAQ:RNAC$8.53 +0.37 (+4.53%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
